Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 33 of 33 entries
Sorted by: Best Match Show Resources per page
Sentinel-node biopsy boosts melanoma treatment.

The Lancet. Oncology

Bagcchi S.
PMID: 24809094
Lancet Oncol. 2014 Mar;15(3):e111. doi: 10.1016/s1470-2045(14)70087-7.

No abstract available.

Cite
Bagcchi S. Sentinel-node biopsy boosts melanoma treatment. Lancet Oncol. 2014;15(3):e111doi: 10.1016/s1470-2045(14)70087-7.
Bagcchi, S. (2014). Sentinel-node biopsy boosts melanoma treatment. The Lancet. Oncology, 15(3), e111. https://doi.org/10.1016/s1470-2045(14)70087-7
Bagcchi, Sanjeet. "Sentinel-node biopsy boosts melanoma treatment." The Lancet. Oncology vol. 15,3 (2014): e111. doi: https://doi.org/10.1016/s1470-2045(14)70087-7
Bagcchi S. Sentinel-node biopsy boosts melanoma treatment. Lancet Oncol. 2014 Mar;15(3):e111. doi: 10.1016/s1470-2045(14)70087-7. PMID: 24809094.
Copy Download .nbib Format: NLM
US Senator John McCain and risk of melanoma-associated mortality.

Lancet (London, England)

Alam J.
PMID: 18970975
Lancet. 2008 Oct 25;372(9648):1462. doi: 10.1016/S0140-6736(08)61618-9.

No abstract available.

Cite
Alam J. US Senator John McCain and risk of melanoma-associated mortality. Lancet. 2008;372(9648):1462doi: 10.1016/S0140-6736(08)61618-9.
Alam, J. (2008). US Senator John McCain and risk of melanoma-associated mortality. Lancet (London, England), 372(9648), 1462. https://doi.org/10.1016/S0140-6736(08)61618-9
Alam, John. "US Senator John McCain and risk of melanoma-associated mortality." Lancet (London, England) vol. 372,9648 (2008): 1462. doi: https://doi.org/10.1016/S0140-6736(08)61618-9
Alam J. US Senator John McCain and risk of melanoma-associated mortality. Lancet. 2008 Oct 25;372(9648):1462. doi: 10.1016/S0140-6736(08)61618-9. PMID: 18970975.
Copy Download .nbib Format: NLM
Sentinel lymph node biopsy for melanoma of the head and neck.

Expert review of anticancer therapy

Lentsch EJ, McMasters KM.
PMID: 14599090
Expert Rev Anticancer Ther. 2003 Oct;3(5):673-83. doi: 10.1586/14737140.3.5.673.

Since its first description nearly two centuries ago, melanoma has been a difficult disease to diagnose and treat. With the incidence and mortality rates slowly increasing, understanding this disease is more important than ever. Herein, the current diagnostic and...

Cite
Lentsch EJ, McMasters KM. Sentinel lymph node biopsy for melanoma of the head and neck. Expert Rev Anticancer Ther. 2003;3(5):673-83doi: 10.1586/14737140.3.5.673.
Lentsch, E. J., & McMasters, K. M. (2003). Sentinel lymph node biopsy for melanoma of the head and neck. Expert review of anticancer therapy, 3(5), 673-83. https://doi.org/10.1586/14737140.3.5.673
Lentsch, Eric J, and McMasters, Kelly M. "Sentinel lymph node biopsy for melanoma of the head and neck." Expert review of anticancer therapy vol. 3,5 (2003): 673-83. doi: https://doi.org/10.1586/14737140.3.5.673
Lentsch EJ, McMasters KM. Sentinel lymph node biopsy for melanoma of the head and neck. Expert Rev Anticancer Ther. 2003 Oct;3(5):673-83. doi: 10.1586/14737140.3.5.673. PMID: 14599090.
Copy Download .nbib Format: NLM
Debulking surgery in advanced melanoma.

Expert review of anticancer therapy

Gajdos C, McCarter MD.
PMID: 22050019
Expert Rev Anticancer Ther. 2011 Nov;11(11):1703-12. doi: 10.1586/era.11.98.

In general, patients with stage IV melanoma have poor survival. However, there are subsets of stage IV melanoma patients who are candidates for surgical debulking. There is a growing body of retrospective evidence about clinicians being able to better...

Cite
Gajdos C, McCarter MD. Debulking surgery in advanced melanoma. Expert Rev Anticancer Ther. 2011;11(11):1703-12doi: 10.1586/era.11.98.
Gajdos, C., & McCarter, M. D. (2011). Debulking surgery in advanced melanoma. Expert review of anticancer therapy, 11(11), 1703-12. https://doi.org/10.1586/era.11.98
Gajdos, Csaba, and McCarter, Martin D. "Debulking surgery in advanced melanoma." Expert review of anticancer therapy vol. 11,11 (2011): 1703-12. doi: https://doi.org/10.1586/era.11.98
Gajdos C, McCarter MD. Debulking surgery in advanced melanoma. Expert Rev Anticancer Ther. 2011 Nov;11(11):1703-12. doi: 10.1586/era.11.98. PMID: 22050019.
Copy Download .nbib Format: NLM
What is there to find in malignant melanoma re-excision specimens?.

Histopathology

Kirkham N.
PMID: 9675598
Histopathology. 1998 Jun;32(6):566-7. doi: 10.1046/j.1365-2559.1998.00435.x.

No abstract available.

Cite
Kirkham N. What is there to find in malignant melanoma re-excision specimens?. Histopathology. 1998;32(6):566-7doi: 10.1046/j.1365-2559.1998.00435.x.
Kirkham, N. (1998). What is there to find in malignant melanoma re-excision specimens?. Histopathology, 32(6), 566-7. https://doi.org/10.1046/j.1365-2559.1998.00435.x
Kirkham, N. "What is there to find in malignant melanoma re-excision specimens?." Histopathology vol. 32,6 (1998): 566-7. doi: https://doi.org/10.1046/j.1365-2559.1998.00435.x
Kirkham N. What is there to find in malignant melanoma re-excision specimens?. Histopathology. 1998 Jun;32(6):566-7. doi: 10.1046/j.1365-2559.1998.00435.x. PMID: 9675598.
Copy Download .nbib Format: NLM
Amelanotic melanoma or poorly differentiated melanoma?.

Journal of cutaneous pathology

Bhawan J.
PMID: 6987283
J Cutan Pathol. 1980 Feb;7(1):55-6. doi: 10.1111/j.1600-0560.1980.tb00978.x.

No abstract available.

Cite
Bhawan J. Amelanotic melanoma or poorly differentiated melanoma?. J Cutan Pathol. 1980;7(1):55-6doi: 10.1111/j.1600-0560.1980.tb00978.x.
Bhawan, J. (1980). Amelanotic melanoma or poorly differentiated melanoma?. Journal of cutaneous pathology, 7(1), 55-6. https://doi.org/10.1111/j.1600-0560.1980.tb00978.x
Bhawan, J. "Amelanotic melanoma or poorly differentiated melanoma?." Journal of cutaneous pathology vol. 7,1 (1980): 55-6. doi: https://doi.org/10.1111/j.1600-0560.1980.tb00978.x
Bhawan J. Amelanotic melanoma or poorly differentiated melanoma?. J Cutan Pathol. 1980 Feb;7(1):55-6. doi: 10.1111/j.1600-0560.1980.tb00978.x. PMID: 6987283.
Copy Download .nbib Format: NLM
Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond.

Annals of surgical oncology

Gershenwald JE, Scolyer RA.
PMID: 29850954
Ann Surg Oncol. 2018 Aug;25(8):2105-2110. doi: 10.1245/s10434-018-6513-7. Epub 2018 May 30.

No abstract available.

Cite
Gershenwald JE, Scolyer RA. Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann Surg Oncol. 2018;25(8):2105-2110doi: 10.1245/s10434-018-6513-7.
Gershenwald, J. E., & Scolyer, R. A. (2018). Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Annals of surgical oncology, 25(8), 2105-2110. https://doi.org/10.1245/s10434-018-6513-7
Gershenwald, Jeffrey E, and Scolyer, Richard A. "Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond." Annals of surgical oncology vol. 25,8 (2018): 2105-2110. doi: https://doi.org/10.1245/s10434-018-6513-7
Gershenwald JE, Scolyer RA. Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann Surg Oncol. 2018 Aug;25(8):2105-2110. doi: 10.1245/s10434-018-6513-7. Epub 2018 May 30. PMID: 29850954.
Copy Download .nbib Format: NLM
Targeted Therapy and Immunotherapy for Melanoma in Japan.

Current treatment options in oncology

Namikawa K, Yamazaki N.
PMID: 30675668
Curr Treat Options Oncol. 2019 Jan 24;20(1):7. doi: 10.1007/s11864-019-0607-8.

OPINION STATEMENT: Melanoma has several clinically and pathologically distinguishable subtypes, which also differ genetically. Mutation patterns vary among different melanoma subtypes, and efficacy of immune-checkpoint inhibitors differs depending on the subtype of melanoma. In spite of the recent revolution...

Cite
Namikawa K, Yamazaki N. Targeted Therapy and Immunotherapy for Melanoma in Japan. Curr Treat Options Oncol. 2019;20(1):7doi: 10.1007/s11864-019-0607-8.
Namikawa, K., & Yamazaki, N. (2019). Targeted Therapy and Immunotherapy for Melanoma in Japan. Current treatment options in oncology, 20(1), 7. https://doi.org/10.1007/s11864-019-0607-8
Namikawa, Kenjiro, and Yamazaki, Naoya. "Targeted Therapy and Immunotherapy for Melanoma in Japan." Current treatment options in oncology vol. 20,1 (2019): 7. doi: https://doi.org/10.1007/s11864-019-0607-8
Namikawa K, Yamazaki N. Targeted Therapy and Immunotherapy for Melanoma in Japan. Curr Treat Options Oncol. 2019 Jan 24;20(1):7. doi: 10.1007/s11864-019-0607-8. PMID: 30675668; PMCID: PMC6344396.
Copy Download .nbib Format: NLM
A review of the AJCC melanoma staging system in the TNM classification (eighth edition).

Japanese journal of clinical oncology

Ogata D, Namikawa K, Takahashi A, Yamazaki N.
PMID: 33709104
Jpn J Clin Oncol. 2021 Apr 30;51(5):671-674. doi: 10.1093/jjco/hyab022.

In the eighth edition of the American Joint Committee on Cancer Staging Manual, several modifications were made for melanoma. These modifications were aimed at improving the prognosis prediction accuracy of the staging system. The main modifications are as follows:...

Cite
Ogata D, Namikawa K, Takahashi A, et al. A review of the AJCC melanoma staging system in the TNM classification (eighth edition). Jpn J Clin Oncol. 2021;51(5):671-674doi: 10.1093/jjco/hyab022.
Ogata, D., Namikawa, K., Takahashi, A., & Yamazaki, N. (2021). A review of the AJCC melanoma staging system in the TNM classification (eighth edition). Japanese journal of clinical oncology, 51(5), 671-674. https://doi.org/10.1093/jjco/hyab022
Ogata, Dai, et al. "A review of the AJCC melanoma staging system in the TNM classification (eighth edition)." Japanese journal of clinical oncology vol. 51,5 (2021): 671-674. doi: https://doi.org/10.1093/jjco/hyab022
Ogata D, Namikawa K, Takahashi A, Yamazaki N. A review of the AJCC melanoma staging system in the TNM classification (eighth edition). Jpn J Clin Oncol. 2021 Apr 30;51(5):671-674. doi: 10.1093/jjco/hyab022. PMID: 33709104.
Copy Download .nbib Format: NLM
Showing 25 to 33 of 33 entries